Prognostic factors in chronic lymphocytic leukemia

Current Hematologic Malignancy Reports

Volumn 2, Issue 1, 2007, Pages 49-55

  Kay, Neil E ^a   Shanafelt, Tait D ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; LACTATE DEHYDROGENASE; PROTEIN KINASE ZAP 70; RITUXIMAB; THYMIDINE KINASE;

CHROMOSOME ABERRATION; CHROMOSOME DELETION; CHROMOSOME MUTATION; CHRONIC LYMPHATIC LEUKEMIA; CYTOPENIA; DISEASE COURSE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LYMPHADENOPATHY; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SOMATIC HYPERMUTATION; SURVIVAL RATE;

AGED; ANTIGENS, CD38; BETA 2-MICROGLOBULIN; BONE MARROW; CHROMOSOME ABERRATIONS; COHORT STUDIES; FEMALE; GENE REARRANGEMENT, B-LYMPHOCYTE, HEAVY CHAIN; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; THYMIDINE KINASE; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 34250755333     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0007-1     Document Type: Review

References (43)

1. Morton LM, Wang SS, Devesa SS, et al.: Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
2. Rai KR, Sawitsky A, Cronkite EP, et al.: Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219-234.
3. Binet JL, Auquier A, Dighiero G, et al.: A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981, 48:198-206.
4. Molica S: Progression and survival studies in early chronic lymphocytic leukemia. Blood 1991, 78:895-899.
5. Keating MJ, Lerner S, Kantarjian HM, et al.: The serum B2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia (CLL) [abstract]. Blood 1995, 86:60.
6. Molica S, Levato D, Cascavilla N, et al.: Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol 1999, 62:117-122.
7. Montserrat E, Sanchez-Bisono J, Vinolas N, Rozman C: Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986, 62:567-575.
8. Seiler T, Dohner H, Stilgenbauer S: Risk stratification in chronic lymphocytic leukemia. Semin Oncol 2006, 33:186-194.
9. Magnac C, Porcher R, Davi F, et al.: Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia 2003, 17:133-137.
10. Matthews C, Catherwood MA, Morris TC, et al.: Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. Eur J Haematol 2006, 77:309-317.
11. Wierda WG, O'Brien SM, Wang X, et al.: Models predictive for survival in untreated patients with CLL at initial presentation and initial treatment [abstract]. J Clin Oncol 2005, 23(suppl): 6593.
12. Deaglio S, Vaisitti T, Aydin S, et al.: In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006, 108:1135-1144.
13. Shanafelt TD, Geyer SM, Kay NE: Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004, 103:1202-1210.
14. Ghia P, Guida G, Stella S, et al: The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003, 101:1262-1269.
15. Gentile M, Mauro FR, Calabrese E, et al.: The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol 2005, 130:549-557.
16. Pittner BT, Shanafelt TD, Kay NE, Jelinek DF: CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia 2005, 19:2264-2272.
17. Zucchetto A, Bomben R, Dal Bo M, et al.: CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance [letter]. Leukemia 2006, 20:523-525; author reply 528-529.
18. Crespo M, Villamor N, Gine E, et al.: ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia. Clin Cancer Res 2006, 12:726-734.
19. Nolz JC, Tschumper RC, Pittner BT, et al.: ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005, 19:1018-1024.
20. Chen L, Widhopf G, Huynh L, et al.: Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609-4614.
21. Crespo M, Bosch F, Villamor N, et al.: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764-1775.
22. Rassenti LZ, Huynh L, Toy TL, et al.: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004, 351:893-901.
23. Hus I, Podhorecka M, Bojarska-Junak A, et al.: The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006, 17:683-690.
24. Dewald GW, Brockman SR, Paternoster SF, et al.: Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003, 121:287-295.
25. Dohner H, Stilgenbauer S, Benner A, et al.: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000, 343:1910-1916.
26. Byrd JC, Gribben JG, Peterson BL, et al.: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006, 24:437-443.
27. Dickinson JD, Gilmore J, Iqbal J, et al.: 11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. Leuk Lymphoma 2006, 47:231-244.
28. Dickinson JD, Joshi A, Iqbal J, et al.: Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect. Int J Mol Med 2006, 17:769-778.
29. Stilgenbauer S, Lichter P, Dohner H: Genetic features of B-cell chronic lymphocytic leukemia. Rev Clin Exp Hematol 2000, 4:48-72.
30. Fink SR, Smoley SA, Stockero KJ, et al.: Loss of TP53 is due to rearrangements involving chromosome region 17p10-p12 in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006, 167:177-181.
31. Lozanski G, Heerema NA, Flinn IW, et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004, 103:3278-3281. This paper is one of the first to describe how a specific therapy could target patients with high-risk CLL as determined by the presence of p53 mutations or deletions.
32. Stilgenbauer S, Kröber A, Busch R, et al.: 17p deletion predicts for inferior overall survival after fludarabine-based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:212a. Abstract 715.
33. Shanafelt TD, Witzig TE, Fink SR, et al.: Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006, 24:4634-4641.
34. Dicker F, Schnittger S, Haferlach T, et al.: Immunostimulatory oligonucleotide-induced metaphase cytogenetics detects chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status and CD38 expression. Blood 2006, 108:3152-3160.
35. Mayr C, Speicher MR, Kofler DM, et al.: Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006, 107:742-751. First description of the use of CpG oligodeoxynucleotides to stimulate CLL B-cell proliferation with subsequent ability to detect clinically important genetic defects.
36. Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
37. Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
38. Thorselius M, Krober A, Murray F, et al.: Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006, 107:2889-2894.
39. Tobin G, Rosen A, Rosenquist R: What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia? Hematol Oncol 2006, 24:7-13.
40. Capello D, Zucchetto A, Degan M, et al.: Immunophenotypic characterization of IgV(H)3-72 B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Res 2006, 30:1197-1199.
41. Degan M, Bomben R, Dal Bo M, et al.: Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. Br J Haematol 2004, 126:29-42.
42. Jelinek DF, Tschumper RC, Geyer SM, et al.: Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001, 115:854-861.
43. Ritgen M, Lange A, Stilgenbauer S, et al.: Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003, 101:2049-2053.